A Phase 1, Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety and Tolerability of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
At a glance
- Drugs UBX-0101 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors UNITY Biotechnology
- 30 Jan 2019 Planned number of patients changed from 64 to 72.
- 30 Jan 2019 Planned End Date changed from 1 Nov 2018 to 1 May 2019.
- 30 Jan 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Apr 2019.